Tyr731

Site Information
QQIDSCTyEAMyNIQ SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448530
Associated spectra: 8 CST

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 2 , 44 , 46 ) , mass spectrometry ( 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ) , mutation of modification site ( 1 , 2 , 29 , 32 , 41 , 42 , 44 , 45 , 46 ) , phospho-antibody ( 2 , 4 , 14 , 31 , 41 , 42 , 43 , 44 , 46 ) , phosphoamino acid analysis ( 46 ) , western blotting ( 2 , 4 , 14 , 44 )
Disease tissue studied:	bladder cancer ( 29 ) , gastric cancer ( 28 ) , leukemia ( 1 , 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 22 , 23 , 24 , 25 , 26 , 27 , 30 , 33 , 34 , 35 , 36 , 37 , 44 ) , acute lymphocytic leukemia ( 30 ) , acute myelogenous leukemia ( 33 , 34 , 35 , 36 , 37 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 ) , chronic myelogenous leukemia ( 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 22 , 23 , 24 , 25 , 26 , 27 ) , T cell leukemia ( 44 ) , lung cancer ( 15 , 16 ) , non-small cell lung cancer ( 15 , 16 ) , non-small cell lung adenocarcinoma ( 15 , 16 ) , neuroblastoma ( 3 , 17 ) , pancreatic cancer ( 38 , 39 , 40 ) , thymoma ( 45 )
Relevant cell line - cell type - tissue:	32D (myeloid) ( 1 ) , 32Dcl3 (myeloid) ( 45 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 32 ) , BxPC-3 (pancreatic) ( 38 , 39 , 40 ) , CHO (fibroblast) ( 42 ) , COS (fibroblast) ( 46 ) , CTV-1 (myeloid) ( 37 ) , HCC827 (pulmonary) ( 16 ) , HEL (erythroid) ( 34 ) , HeLa (cervical) ( 14 ) , Hs746T (pancreatic) ( 28 ) , HT-93 (myeloid) ( 35 ) , HUVEC (endothelial) ( 2 ) , Jurkat (T lymphocyte) ( 11 , 18 , 19 , 20 , 21 , 31 , 44 , 46 ) , K562 (erythroid) ( 5 , 6 , 7 , 8 , 9 , 10 , 12 , 13 , 22 , 23 , 24 , 25 , 26 , 27 ) , KBM-3 (myeloid) ( 36 ) , LAN-6 (neural crest) ( 3 , 17 ) , Nb2 (thymocyte) ( 45 ) , NCI-H441 (pulmonary) ( 15 ) , platelet-blood ( 4 ) , RAW 264 (macrophage) ( 41 ) , SEM (B lymphocyte) ( 30 ) , SYF (fibroblast) ( 42 ) , T24 (bladder cell) ( 29 ) , T47D (breast cell) ( 43 ) , TF-1 (erythroid) ( 1 ) , UT-7 (myeloid) ( 33 )

Upstream Regulation
Regulatory protein:	PTPRJ (human) ( 14 )
Putative in vivo kinases:	Fyn (human) ( 46 ) , Lck (human) ( 46 ) , Src (human) ( 41 , 42 , 43 ) , Syk (human) ( 46 )
Kinases, in vitro:	Fyn (human) ( 45 )
Treatments:	antibody ( 31 , 44 , 46 ) , EGF ( 14 , 42 , 43 ) , fibrinogen ( 4 ) , OXSI-2 ( 4 ) , PAR4-activating_peptide ( 4 ) , PP1 ( 43 ) , PP2 ( 4 , 41 ) , SC-57101 ( 4 ) , vanadate ( 46 )

Downstream Regulation
Effects of modification on CBL:	activity, induced ( 41 ) , enzymatic activity, induced ( 1 ) , intracellular localization ( 2 ) , molecular association, regulation ( 1 , 2 , 43 , 44 , 45 ) , phosphorylation ( 29 ) , protein conformation ( 2 ) , protein degradation ( 42 )
Effects of modification on biological processes:	cell growth, altered ( 42 ) , cell growth, induced ( 1 ) , cell motility, altered ( 32 ) , signaling pathway regulation ( 1 , 4 )
Induce interaction with:	CTNNA1 (human) ( 2 ) , PIK3CA (human) ( 44 ) , PIK3R1 (human) ( 1 , 43 ) , PIK3R1 (rat) ( 45 ) , Src (human) ( 42 )

References
1	Belizaire R, et al. (2021) CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Blood 137 33512474 Curated Info
2	Shivanna S, et al. (2015) The c-Cbl Ubiquitin Ligase Regulates Nuclear β-Catenin and Angiogenesis by Its Tyrosine Phosphorylation Mediated through the Wnt Signaling Pathway. J Biol Chem 290, 12537-46 25784557 Curated Info
3	Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130 25884760 Curated Info
4	Buitrago L, Langdon WY, Sanjay A, Kunapuli SP (2011) Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling. Blood 118, 5631-40 21967979 Curated Info
5	Moritz A (2011) CST Curation Set: 11304; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
6	Moritz A (2011) CST Curation Set: 11308; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
7	Moritz A (2011) CST Curation Set: 11309; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
8	Moritz A (2011) CST Curation Set: 11310; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
9	Moritz A (2011) CST Curation Set: 11311; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
10	Moritz A (2010) CST Curation Set: 8833; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
11	Guo A (2010) CST Curation Set: 9182; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
12	Moritz A (2010) CST Curation Set: 9049; Year: 2010; Biosample/Treatment: cell line, K562/untreated & calyculin_A; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Moritz A (2010) CST Curation Set: 9050; Year: 2010; Biosample/Treatment: cell line, K562/untreated & calyculin_A; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416 Curated Info
14	Tarcic G, et al. (2009) An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol 19, 1788-98 19836242 Curated Info
15	Moritz A (2009) CST Curation Set: 7849; Year: 2009; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
16	Moritz A (2009) CST Curation Set: 7291; Year: 2009; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
17	Guo A (2009) CST Curation Set: 6125; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Farnsworth C (2009) CST Curation Set: 6184; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Possemato A (2008) CST Curation Set: 5055; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Farnsworth C (2008) CST Curation Set: 4719; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Farnsworth C (2008) CST Curation Set: 4457; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
22	Moritz A (2007) CST Curation Set: 3237; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
23	Moritz A (2007) CST Curation Set: 2779; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
24	Possemato A (2007) CST Curation Set: 2683; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
25	Moritz A (2007) CST Curation Set: 2447; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Moritz A (2007) CST Curation Set: 2407; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
27	Moritz A (2007) CST Curation Set: 2411; Year: 2007; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
28	Guo A (2006) CST Curation Set: 1937; Year: 2006; Biosample/Treatment: cell line, Hs746T/-; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
29	Koga F, et al. (2006) Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci U S A 103, 11318-22 16844778 Curated Info
30	Gu T (2006) CST Curation Set: 1459; Year: 2006; Biosample/Treatment: cell line, SEM/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
31	Houtman JC, et al. (2005) Early phosphorylation kinetics of proteins involved in proximal TCR-mediated signaling pathways. J Immunol 175, 2449-58 16081816 Curated Info
32	Teckchandani AM, Panetti TS, Tsygankov AY (2005) c-Cbl regulates migration of v-Abl-transformed NIH 3T3 fibroblasts via Rac1. Exp Cell Res 307, 247-58 15922744 Curated Info
33	Gu T (2005) CST Curation Set: 758; Year: 2005; Biosample/Treatment: cell line, UT-7/elastase; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
34	Goss V (2004) CST Curation Set: 428; Year: 2004; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
35	Goss V (2004) CST Curation Set: 429; Year: 2004; Biosample/Treatment: cell line, HT-93/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
36	Goss V (2004) CST Curation Set: 430; Year: 2004; Biosample/Treatment: cell line, KBM-3/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
37	Goss V (2004) CST Curation Set: 431; Year: 2004; Biosample/Treatment: cell line, CTV-1/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
38	Guo A (2004) CST Curation Set: 412; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF &'\|\|' Iressa/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
39	Guo A (2004) CST Curation Set: 392; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/none/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
40	Guo A (2004) CST Curation Set: 393; Year: 2004; Biosample1/Treatment/Isotope: cell line, BxPC-3/EGF/L, Biosample2/Treatment/Isotope: cell line, BxPC-3/EGF/Iressa/H; Disease: pancreatic carcinoma; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
41	Miyazaki T, et al. (2004) Src kinase activity is essential for osteoclast function. J Biol Chem 279, 17660-6 14739300 Curated Info
42	Bao J, Gur G, Yarden Y (2003) Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A 100, 2438-43 12604776 Curated Info
43	Kassenbrock CK, et al. (2002) Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor. J Biol Chem 277, 24967-75 11994282 Curated Info
44	van Leeuwen JE, Paik PK, Samelson LE (1999) Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase association. J Biol Chem 274, 5153-62 9988765 Curated Info
45	Hunter S, Burton EA, Wu SC, Anderson SM (1999) Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 274, 2097-106 9890970 Curated Info
46	Feshchenko EA, Langdon WY, Tsygankov AY (1998) Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells. J Biol Chem 273, 8323-31 9525940 Curated Info